-
公开(公告)号:US12134722B2
公开(公告)日:2024-11-05
申请号:US17760519
申请日:2020-06-01
Inventor: Chang-Koo Kim , Jun-Hyun Kim , Jin-Su Park
IPC: C09K13/00 , H01J37/32 , H01L21/311
Abstract: Disclosed is a plasma etching method including a first step of providing a mixed gas containing argon gas and vaporized 1,1,2,2-tetrafluoroethyl-2,2,2-trifluoroethyl ether having a molecular structure of a following Chemical Formula 1 to a plasma chamber in which an etching target is disposed; and a second step of etching the etching target using plasma generated from the mixed gas:
-
292.
公开(公告)号:US20240316249A1
公开(公告)日:2024-09-26
申请号:US18674215
申请日:2024-05-24
Inventor: Moon Suk KIM , Seung Hun Park , Hyeon Jin Ju
CPC classification number: A61L27/52 , A61L27/20 , A61L27/54 , A61L27/56 , A61L2400/06
Abstract: The present invention relates to an injection formulation composition for use as a filler or a drug carrier through a click chemistry reaction. More specifically, the present invention relates to an injection formulation composition comprising: a first liquid comprising a first biopolymer having a first click chemistry functional group introduced thereinto; and a second liquid comprising a second biopolymer having a second click chemistry functional group introduced thereinto, wherein the first click chemistry functional group is chemically linkable with the second click chemistry functional group, to a method for preparing an injection formulation hydrogel using the composition, and to a medical filler, an in-vivo injection type supporter, or a drug carrier using the composition.
-
公开(公告)号:US20240309045A1
公开(公告)日:2024-09-19
申请号:US18279772
申请日:2022-04-20
Inventor: Sangdun CHOI , Bilal Anmad RATHER
CPC classification number: C07K7/08 , A61P29/00 , C07K7/06 , C07K2319/00
Abstract: An inflammasome activates caspase-1 for cytokine maturation and cell death, and thus induces host defense in cells. An NLRP3 inflammasome promotes the release of highly inflammatory cytokines IL-1β and IL-18 to induce gasdermin D-mediated pyroptosis (pyroptotic cell death), and thus is involved in inflammatory processes. Therefore, targeting an NLRP3 pathway and modulating relevant immune responses can be a promising strategy for designing drug candidates for inflammatory diseases. A rationally designed α2-helix-based peptide NIP3 inhibits the NLRP3 pathway. NIP3 has remarkably inhibited both the secretion of NLRP3-induced IL-1β and IL-18 and the expression of downstream proteins in lipopolysaccharide-primed nigericin-activated THP-1 cells. In addition, binding energy data suggests that NIP3 has a stronger affinity for ASCPYD than for NLRP3PYD. Therefore, according to empirical and in silico results, NIP3 exclusively inhibits the NLRP3-ASC-caspase-1 pathway.
-
公开(公告)号:US20240303505A1
公开(公告)日:2024-09-12
申请号:US18595389
申请日:2024-03-04
Inventor: Young-Bae Ko , June-Pyo Jung
IPC: G06N3/098
CPC classification number: G06N3/098
Abstract: Disclosed are a federated learning method and device using device clustering. The federated learning method includes obtaining an arbitrary client group including some clients as a result of performing clustering on a plurality of clients; determining one of the some clients as a leader client based on a centroid associated with the clustering, wherein the leader client receives data associated with at least one parameter of a pre-trained model from each of the some clients; determining at least one client among the some clients as a target client based on an amount of computing resources of the pre-trained model and a training loss of the pre-trained model; and receiving some data associated with at least one parameter of the model of the target client from the leader client, wherein the some data is included in the data.
-
公开(公告)号:US20240255410A1
公开(公告)日:2024-08-01
申请号:US18007348
申请日:2021-07-28
Inventor: Hyun Chul YOON , Jae-Ho KIM , Ka Ram KIM
IPC: G01N15/1434 , G01N21/51 , G01N33/483
CPC classification number: G01N15/1434 , G01N21/51 , G01N33/4833
Abstract: The present invention provides a cell measurement device and method in which retroreflective particles are introduced to measure cells, and thus, an optical signal is obtained without fixing of life activity of cells and performing a separate staining process. An example of the use of retroreflection-based cytometry is evaluation of cell migration. The cells capture the retroreflective particles during cell migration or growth, and migrate in a state that the particles are captured in the cell or bind to the cells. The migrated cells are observed in a form of bright dots inside the cells under irradiation of white light as a non-spectroscopic light source to the cells in the retroreflective optical system. The number of bright spots is counted, and thus, the number of cells and the presence thereof thus can be easily measured based on an image.
-
公开(公告)号:US12039010B2
公开(公告)日:2024-07-16
申请号:US17563663
申请日:2021-12-28
Inventor: Won Jun Hwang , Jae Min Na
IPC: G06K9/62 , G06F18/214
CPC classification number: G06F18/2148
Abstract: The present invention relates to a method and apparatus for unsupervised domain adaptation, including the steps of generating a first augmented domain associated with a source domain, generating a second augmented domain associated with a target domain, and performing unsupervised domain adaptation by using the first augmented domain and the second augmented domain as a bridge for connecting the source domain and the target domain, and it is possible to apply to other exemplary embodiments.
-
公开(公告)号:US20240182552A1
公开(公告)日:2024-06-06
申请号:US18285862
申请日:2022-04-06
Inventor: Dong Ho Nahm
CPC classification number: C07K16/18 , A61P35/00 , A61P37/08 , C07K16/065 , A61K2039/505
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating immune dysregulation-related diseases, including oxidized immunoglobulin as an active ingredient and a preventive or therapeutic method using same, a pharmaceutical composition for treating allergic diseases, chronic inflammatory diseases, autoimmune diseases or malignant tumor diseases, including as an active ingredient oxidized immunoglobulin obtained through artificially induced oxidation; and a novel immunomodulatory therapy which, by administering the composition to patients with the diseases, is differentiated from existing immunoglobulin therapeutic agents and more effective.
-
公开(公告)号:US11989347B2
公开(公告)日:2024-05-21
申请号:US17528509
申请日:2021-11-17
Inventor: Bongsu Shin , Jesung Koh , Hongseok Lee , Dongjin Kim , Baekgyeom Kim
CPC classification number: G06F3/016 , A41D19/0024 , G06F3/014
Abstract: There is provided a haptic glove apparatus including a glove-shaped base portion and at least one actuator disposed on the base portion. The at least one actuator includes a driving force applying portion extending in a first direction and expanding or contracting in the first direction, and an elastic support portion disposed to surround the driving force applying portion and expanding or contracting in a second direction perpendicular to the first direction according to the expansion or the contraction of the driving force applying portion.
-
299.
公开(公告)号:US20240152691A1
公开(公告)日:2024-05-09
申请号:US18363622
申请日:2023-08-01
Inventor: Inyoung PARK , Tae-Sun CHUNG
IPC: G06F40/169 , G06F3/01
CPC classification number: G06F40/169 , G06F3/013
Abstract: Disclosed herein a method and apparatus for providing a comment interface to encourage writing high-quality comments. The method includes: acquiring comment history information of a comment user who wants to enter a comment, based on user information of the comment user, determining a gaze effect of gazing the comment of the comment user among preset gaze effects based on the comment history information, and providing a comment interface including the determined gaze effect to the comment user.
-
公开(公告)号:US20240150407A1
公开(公告)日:2024-05-09
申请号:US18554481
申请日:2022-04-01
Inventor: Seong Hyang SOHN
CPC classification number: C07K14/001 , A23L33/18 , A61K47/56 , A61P37/06
Abstract: The present invention relates to: a peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS: 4 to 7 or a fragment thereof; and a pharmaceutical composition for the treatment or prevention of inflammatory diseases or autoimmune diseases, comprising same. The peptide has been confirmed to have an excellent effect of inhibiting cytokines such as IL-17 and TNF alpha, and thus can be provided as a therapeutic agent for various inflammatory diseases, including Behcet's disease.
-
-
-
-
-
-
-
-
-